GlassScriptPhysician profile
Deanna Minor
NPI 1376912386
$6,071.74
in general payments reported to CMS, 2019-2025
20 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $543 · 2023: $1,682 · 2024: $1,839 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,525 · Education: $3.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,524.56 |
| Education | $3.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $870.59 | 2021-2025 | Ingrezza |
| Abbvie INC. | $785.98 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $761.94 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $598.17 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $538.60 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $532.84 | 2023-2025 | Caplyta |
| Lundbeck LLC | $380.38 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $350.47 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $231.13 | 2024-2025 | Invega Sustenna |
| Braeburn INC. | $194.56 | 2024-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $186.01 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $138.58 | 2021 | |
| Ironshore Pharmaceuticals INC. | $128.99 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $118.48 | 2023-2024 | Fanapt, Hetlioz |
| Indivior INC. | $90.54 | 2023-2024 | Perseris, Sublocade |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $75.34 | 2023 | Auvelity |
| Corium, LLC | $34.15 | 2023 | Azstarys |
| Bioxcel Therapeutics, INC. | $24.77 | 2024 | Igalmi |
| Collegium Pharmaceutical, INC. | $16.22 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $14.00 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Minor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.